

Financial news for ACOR dated on 2020-06-08: Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.

Financial news for ACOR dated on 2020-05-14: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for ACOR dated on 2020-05-06: H.C. Wainwright Reiterates Neutral on Acorda Therapeutics, Lowers Price Target to \$5

Financial news for ACOR dated on 2020-05-05: Acorda Therapeutics Q1 EPS \$(0.510) Misses \$(0.350) Estimate, Sales \$28.099M Miss \$41.010M Estimate

Financial news for ACOR dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for ACOR dated on 2020-05-04: 20 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ACOR dated on 2020-05-04: 30 Stocks Moving in Monday's Pre-Market Session

Financial news for ACOR dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for ACOR dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for ACOR dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for ACOR dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for ACOR dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for ACOR dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for ACOR dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lilly, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for ACOR dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for ACOR dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for ACOR dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for ACOR dated on 2020-02-13: Acorda Therapeutics Sees FY20 Sales \$130-\$160M Vs. \$149.21M Est.

Financial news for ACOR dated on 2020-02-13: Acorda Therapeutics Q4 EPS \$(0.15) Beats \$(0.40) Estimate, Sales \$50.496M Beat \$44.58M Estimate

Financial news for ACOR dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for ACOR dated on 2020-01-27: 70 Biggest Movers From Friday

Financial news for ACOR dated on 2020-01-24: 52 Biggest Movers From Yesterday

Financial news for ACOR dated on 2020-01-23: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for ACOR dated on 2020-01-23: 146 Biotechnology Stocks Moving In Thursday's Session

Financial news for ACOR dated on 2020-01-16: 21 Stocks Moving in Thursday's Pre-Market Session

Financial news for ACOR dated on 2020-01-16: 75 Biggest Movers From Yesterday

Financial news for ACOR dated on 2020-01-15: Acorda Therapeutics shares are trading lower after the company filed a common stock offering by selling shareholders of roughly 9.6 million shares.

Financial news for ACOR dated on 2020-01-15: Acorda Therapeutics Files For ~9.6M Share Common Stock Offering By Selling Shareholders

Financial news for ACOR dated on 2020-01-15: Mid-Afternoon Market Update: OrganiGram Rises Following Q1 Results; Nektar Therapeutics Shares Plummet

Financial news for ACOR dated on 2020-01-15: Mid-Day Market Update: Concrete Pumping Falls On Weak Q4 Results; Fluent Shares Jump

Financial news for ACOR dated on 2020-01-15: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ACOR dated on 2020-01-15: Acorda Therapeutics shares are trading lower after the company issued FY19 and FY20 guidance.

Financial news for ACOR dated on 2020-01-15: Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Reports Mixed Q4 Results

Financial news for ACOR dated on 2020-01-15: 34 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACOR dated on 2020-01-15: Acorda Sees Prelim. FY19 Total Net Product Revenue ~\$178M, Sees FY20 Sales \$130M-\$160M vs \$143.9M Est.

Financial news for ACOR dated on 2020-01-08: 50 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACOR dated on 2020-01-07: 15 Stocks Moving in Tuesday's Pre-Market Session

Financial news for ACOR dated on 2020-01-06: 53 Biggest Movers From Friday

Financial news for ACOR dated on 2020-01-03: Mid-Afternoon Market Update: Dow Slides Over 200 Points; Landec Shares Drop On Q2 Earnings

Financial news for ACOR dated on 2020-01-03: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for ACOR dated on 2020-01-03: Mid-Day Market Update: Novan Falls On Failed Study; Acorda Therapeutics Shares Surge

Financial news for ACOR dated on 2020-01-03: Mid-Morning Market Update: Markets Open Lower; Lamb Weston Posts Upbeat Q2 Earnings

Financial news for ACOR dated on 2020-01-03: Acorda Therapeutics shares are trading higher after Point72 reported a 9.8% passive stake in the company.

Financial news for ACOR dated on 2020-01-03: The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

Financial news for ACOR dated on 2020-01-03: 34 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ACOR dated on 2020-01-03: 18 Stocks Moving in Friday's Pre-Market Session

Financial news for ACOR dated on 2020-01-02: Point72 Reports 9.8% Passive Stake In Acorda Therapeutics

Financial news for ACOR dated on 2019-12-31: 55 Biggest Movers From Yesterday

Financial news for ACOR dated on 2019-12-30: Mid-Afternoon Market Update: Dow Down 150 Points; Savara Shares Spike Higher

Financial news for ACOR dated on 2019-12-30: Acorda Therapeutics shares are trading lower. Not seeing any news to justify the price action.

Financial news for ACOR dated on 2019-12-30: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for ACOR dated on 2019-12-27: Mid-Day Market Update: Dow Up 70 Points; Pintec Technology Shares Spike Higher

Financial news for ACOR dated on 2019-12-27: 46 Stocks Moving In Friday's Mid-Day Session

Financial news for ACOR dated on 2019-12-27: Acorda Therapeutics shares are trading lower as a potential sell-off after the stock increased roughly 40% yesterday.

Financial news for ACOR dated on 2019-12-27: Mid-Morning Market Update: Markets Mostly Higher; Flexion Receives FDA Nod For Zilretta Label Expansion

Financial news for ACOR dated on 2019-12-27: 31 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ACOR dated on 2019-12-27: 28 Stocks Moving in Friday's Pre-Market Session

Financial news for ACOR dated on 2019-12-27: 60 Biggest Movers From Yesterday

Financial news for ACOR dated on 2019-12-26: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for ACOR dated on 2019-12-26: Acorda Therapeutics shares are trading higher. Not seeing any news to justify the price action.

Financial news for ACOR dated on 2019-12-12: Acorda Therapeutics shares are trading higher. Not currently seeing any company-specific news.

Financial news for ACOR dated on 2019-12-05: 72 Biggest Movers From Yesterday

Financial news for ACOR dated on 2019-12-04: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ACOR dated on 2019-12-03: Acorda Therapeutics shares are trading higher. Not currently seeing any news to justify the price action.

Financial news for ACOR dated on 2019-11-21: Acorda Therapeutics shares are trading higher, potentially rebounding after the stock dropped ~39% over the past 10 trading sessions.

Financial news for ACOR dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for ACOR dated on 2019-11-20: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ACOR dated on 2019-11-20: The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for ACOR dated on 2019-11-12: Acorda Therapeutics Announce That Jane Wasman, President, International & General Counsel, Is Resigning From The Company Effective At The End Of This Year

Financial news for ACOR dated on 2019-11-07: Biotech Stock On The Radar: Alkermes At A Crossroads

Financial news for ACOR dated on 2019-11-05: Acorda Therapeutics shares are trading higher after the company reported better-than-expected Q3 sales results.

Financial news for ACOR dated on 2019-11-04: Acorda Therapeutics Q3 GAAP EPS \$(5.55), Sales \$47.722M Beat \$43.82M Estimate

Financial news for ACOR dated on 2019-11-04: Acorda Q3 INBRIJA Net Sales \$5M; Sees FY19 Year-End Cash Balance \$225M+

Financial news for ACOR dated on 2019-11-01: Acorda Therapeutics shares are trading higher. Not seeing any news to justify the price action.

Financial news for ACOR dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for ACOR dated on 2019-11-01: 23 Biggest Movers From Yesterday

Financial news for ACOR dated on 2019-10-31: Acorda Therapeutics shares are trading lower in sympathy with the weakness in the overall market.

Financial news for ACOR dated on 2019-10-31: 27 Stocks Moving In Thursday's Mid-Day Session

Financial news for ACOR dated on 2019-10-30: Stocks That Hit 52-Week Lows On

Wednesday

Financial news for ACOR dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for ACOR dated on 2019-10-25: Stocks That Hit 52-Week Lows On Friday

Financial news for ACOR dated on 2019-10-24: 21 Stocks Moving In Thursday's Mid-Day Session

Financial news for ACOR dated on 2019-10-24: Benzinga's Top Upgrades, Downgrades For October 24, 2019

Financial news for ACOR dated on 2019-10-24: Acorda Therapeutics shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight

Financial news for ACOR dated on 2019-10-24: The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

Financial news for ACOR dated on 2019-10-24: JP Morgan Downgrades Acorda Therapeutics to Underweight

Financial news for ACOR dated on 2019-10-24: 41 Biggest Movers From Yesterday

Financial news for ACOR dated on 2019-10-23: Acorda Therapeutics Announces Corporate Restructuring; Co. To Reduce Headcount By 25%, Expects Annualized Cost Savings ~\$21M

Financial news for ACOR dated on 2019-10-23: Acorda Therapeutics shares are trading higher. Not seeing any news to justify the price action.

Financial news for ACOR dated on 2019-10-14: 58 Biggest Movers From Friday

Financial news for ACOR dated on 2019-10-07: Supreme Court Declines To Hear Acorda Therapeutics' Appeal In Patent Dispute Over Multiple Sclerosis Drug Ampyra

Financial news for ACOR dated on 2019-10-04: Acorda's Inbrija Now Available In US Without Need For Medical Exception For ~66% Of Commercial, ~25% Of Medicare Plan Patients

Financial news for ACOR dated on 2019-10-03: 21 Stocks Moving in Thursday's Pre-Market Session

Financial news for ACOR dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for ACOR dated on 2019-09-25: 58 Biggest Movers From Yesterday

Financial news for ACOR dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for ACOR dated on 2019-09-24: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ACOR dated on 2019-09-24: Acorda Therapeutics shares are trading lower despite the company announcing that its Inbrija 33mg Inhalation powder and hard capsules was granted marketing authorization by the European Commission.

Financial news for ACOR dated on 2019-09-24: Acorda Therapeutics Says European Commission Granted Marketing Authorization For Inbrija 33mg Inhalation Powder, Hard Capsules; Marketing Authorization Approves Inbrija For Use In 28 EU Countries, As Well As Iceland, Norway And Liechtenstein

Financial news for ACOR dated on 2019-09-11: 80 Biggest Movers From Yesterday

Financial news for ACOR dated on 2019-09-10: 84 Biggest Movers From Yesterday

Financial news for ACOR dated on 2019-09-09: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for ACOR dated on 2019-08-16: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for ACOR dated on 2019-08-15: Stocks That Hit 52-Week Lows On Thursday

Financial news for ACOR dated on 2019-08-15: 26 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for ACOR dated on 2019-08-15: The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings

Financial news for ACOR dated on 2019-08-14: Acorda Therapeutics shares are trading lower after H.C. Wainwright downgraded the stock from Buy to Neutral and lowered the price target from \$31 to \$6.

Financial news for ACOR dated on 2019-08-14: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ACOR dated on 2019-08-14: Benzinga's Top Upgrades, Downgrades For August 14, 2019

Financial news for ACOR dated on 2019-08-14: H.C. Wainwright Downgrades Acorda Therapeutics to Neutral, Lowers Price Target to \$6

Financial news for ACOR dated on 2019-08-14: The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

Financial news for ACOR dated on 2019-08-13: Stocks That Hit 52-Week Lows On Tuesday

Financial news for ACOR dated on 2019-08-06: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for ACOR dated on 2019-08-05: New 52-Week Lows For Monday Morning

Financial news for ACOR dated on 2019-08-05: 82 Biggest Movers From Friday

Financial news for ACOR dated on 2019-08-02: 29 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for ACOR dated on 2019-08-02: Mid-Afternoon Market Update: Crude Oil Up Over 3%; Natural Grocers Shares Spike Higher

Financial news for ACOR dated on 2019-08-02: 60 Stocks Moving In Friday's Mid-Day Session

Financial news for ACOR dated on 2019-08-02: Stifel Maintains Hold on Acorda Therapeutics, Lowers Price Target to \$7

Financial news for ACOR dated on 2019-08-02: Mid-Day Market Update: BlackLine Surges Following Upbeat Q2 Results; Glu Mobile Shares Slide

Financial news for ACOR dated on 2019-08-02: Wedbush Reiterates Neutral on Acorda Therapeutics, Lowers Price Target to \$7

Financial news for ACOR dated on 2019-08-02: Stocks That Set New 52-Week Lows Friday Morning

Financial news for ACOR dated on 2019-08-02: Mid-Morning Market Update: Markets Open Lower; Exxon Mobil Earnings Beat Estimates

Financial news for ACOR dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for ACOR dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for ACOR dated on 2019-07-26: Acorda Reports Received Positive CHMP Opinion For INBRIJA

Financial news for ACOR dated on 2019-07-02: Acorda Therapeutics Option Alert: Oct 18 \$7 Puts Sweep (25) below Bid!: 630 @ \$1.101 vs 1094 OI; Earnings 8/1 Before Open [est] Ref=\$7.77

Financial news for ACOR dated on 2019-06-27: The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO

Financial news for ACOR dated on 2019-06-13: The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetrphase Downsizes

Financial news for ACOR dated on 2019-06-07: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

Financial news for ACOR dated on 2019-06-07: 55 Biggest Movers From Yesterday

Financial news for ACOR dated on 2019-06-06: 42 Stocks Moving In Thursday's Mid-Day Session

Financial news for ACOR dated on 2019-06-06: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

Financial news for ACOR dated on 2019-06-06: 66 Biggest Movers From Yesterday

Financial news for ACOR dated on 2019-06-05: 44 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ACOR dated on 2019-05-31: The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

Financial news for ACOR dated on 2019-05-23: Wedbush Initiates Coverage On Acorda Therapeutics, Inc. - Common Stock with Neutral Rating, Announces \$12 Price Target

Financial news for ACOR dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for ACOR dated on 2019-05-02: Acorda Therapeutics Q1 Adj. EPS \$(0.56) Beats \$(0.94) Estimate, Sales \$41.334M Beat \$33.04M Estimate

Financial news for ACOR dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for ACOR dated on 2019-04-23: The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale

Financial news for ACOR dated on 2019-04-18: The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio

Financial news for ACOR dated on 2019-04-16: The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

Financial news for ACOR dated on 2019-04-12: The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug

Financial news for ACOR dated on 2019-04-10: The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering

Financial news for ACOR dated on 2019-03-19: Acorda To Present New Long-Term Data For INBRIJA At Academy Of Managed Care Pharmacy Annual Meeting

Financial news for ACOR dated on 2019-02-28: Acorda Therapeutics Reports Commercial Launch Of INBRIJA

Financial news for ACOR dated on 2019-02-19: 61 Biggest Movers From Friday

Financial news for ACOR dated on 2019-02-15: 52 Stocks Moving In Friday's Mid-Day Session

Financial news for ACOR dated on 2019-02-15: Acorda Therapeutics Late Thursday Reported Q4 EPS \$0.45 Beats \$(0.63) Estimate, Sales \$69.152M Beat \$52.54M Estimate

Financial news for ACOR dated on 2019-02-15: The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal

Financial news for ACOR dated on 2019-02-14: The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial

Financial news for ACOR dated on 2019-02-10: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for ACOR dated on 2019-01-23: Acorda Therapeutics Amended 13D Filing From Scopia Capital Shows Cut Stake From ~7.1M Shares To ~4.8M Shares, Or 10.1% Stake

Financial news for ACOR dated on 2018-12-31: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Financial news for ACOR dated on 2018-12-26: Acorda's Prospects Remain Dubious Despite Inbrija Approval, Says Bearish Raymond James

Financial news for ACOR dated on 2018-12-26: 55 Biggest Movers From Monday

Financial news for ACOR dated on 2018-12-24: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for ACOR dated on 2018-12-24: Mid-Morning Market Update: Markets Open Lower; Vista Equity Partners to Acquire Mindbody For \$36.50/Share

Financial news for ACOR dated on 2018-12-24: Acorda Therapeutics shares are trading higher after announcing FDA approval of INBRIJA.

Financial news for ACOR dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for ACOR dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for ACOR dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for ACOR dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for ACOR dated on 2018-12-12: 48 Biggest Movers From Yesterday

Financial news for ACOR dated on 2018-12-11: 34 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ACOR dated on 2018-12-11: Acorda Therapeutics shares are trading lower after Goldman Sachs lowered its rating on the stock from neutral to sell and announced a \$10 price target.

Financial news for ACOR dated on 2018-12-11: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ACOR dated on 2018-12-11: Goldman Sachs Downgrades Acorda Therapeutics to Sell, Lowers Price Target to \$10

Financial news for ACOR dated on 2018-11-05: Germany-Based Pharmaceutical Company Grunenthal Acquires Global Commercial Rights For Qutenza Dermal Pain Patch From Acorda Therapeutics

Financial news for ACOR dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for ACOR dated on 2018-10-31: Acorda Therapeutics Raises FY18 AMPYRA Sales Guidance From \$330M-\$350M To Over \$400M

Financial news for ACOR dated on 2018-10-31: Acorda Therapeutics Q3 Adj. EPS \$0.17 Beats \$(0.02) Estimate, Sales \$142.814M Beat \$82.81M Estimate

Financial news for ACOR dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for ACOR dated on 2018-10-18: Acorda 8-K From Earlier Showed Co. Received Letters From FDA Related To Pre-Approval Inspections Of Co.'s Chelsea, Massachusetts Manufacturing Facility, Inbrija Inhaler Device Facility, Indicated Inspections Closed Without Need For Further Actions

Financial news for ACOR dated on 2018-10-18: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACOR dated on 2018-10-18: Acorda Therapeutics shares are trading higher after the company reported the FDA closed its inspections of facilities in Massachusetts without need for further action.

Financial news for ACOR dated on 2018-10-14: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for ACOR dated on 2018-10-08: The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

Financial news for ACOR dated on 2018-10-05: Stifel Nicolaus Maintains Hold on Acorda Therapeutics, Lowers Price Target to \$19

Financial news for ACOR dated on 2018-09-14: Stocks Which Set New 52-Week Low Yesterday, September 13th

Financial news for ACOR dated on 2018-09-13: Acorda Therapeutics Reports FDA Extension Of INBRIJA New Drug Application Review Period PDUFA Date From Oct. 5, 2018 To Jan. 5, 2019

Financial news for ACOR dated on 2018-09-11: 51 Biggest Movers From Yesterday

Financial news for ACOR dated on 2018-09-10: Mid-Afternoon Market Update: Dow Edges Lower; Acorda Therapeutics Shares Plunge

Financial news for ACOR dated on 2018-09-10: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for ACOR dated on 2018-09-10: Acorda Therapeutics shares are down 20.6% following a press release indicating US Court of Appeals upheld a Delaware decision to invalidate 4 AMPYRA patents.

Financial news for ACOR dated on 2018-09-10: Acorda Issues Press Release Highlighting US Appeals Court Upheld Delaware Decision To Invalidate 4 AMPYRA Patents In 2-1 Vote

Financial news for ACOR dated on 2018-09-10: Acorda Therapeutics Shares Down 21.3% After Earlier Report It Has Lost An Patent Court Appeal Ruling Regarding The Drug Ampyra, Affirming A Trial Ruling In Favor Of Teva and Mylan

Financial news for ACOR dated on 2018-08-23: Cantor Fitzgerald Initiates Coverage On Acorda Therapeutics with Neutral Rating, Announces \$32 Price Target

Financial news for ACOR dated on 2018-08-14: Acorda Announces Management Transitions

Financial news for ACOR dated on 2018-08-07: Stifel Nicolaus Reinstates Hold on Acorda Therapeutics, Lowers Price Target to \$25

Financial news for ACOR dated on 2018-08-03: UPDATE: Acorda Says Co. Signed Interim Deal With Hikma For Ampyra Time Period For Until Federal Circuit Issues Decision On Merits Of Appellate Proceeding

Financial news for ACOR dated on 2018-08-03: UPDATE: Acorda Says Has Signed Interim Deal With Teva For Ampyra Time Period Until Aug. 31, 2018

Financial news for ACOR dated on 2018-08-03: UPDATE: Acorda Says Mylan Will Be Permitted To Market Its Generic Version Of Ampyra In US Sometime In 2025 Or Earlier Under Certain Circumstances

Financial news for ACOR dated on 2018-08-03: Acorda 8-K Shows Updates On Litigation With Mylan, Teva, West-Ward Pharma, Hikma Related To Ampyra Orange Book-Listed Patents: Entered Into Conditional Settlement Deal

Financial news for ACOR dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for ACOR dated on 2018-08-02: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for ACOR dated on 2018-08-02: Acorda Sees FY18 AMPYRA Net Rev. Guidance Of \$330-\$350M

Financial news for ACOR dated on 2018-08-02: Acorda Therapeutics Q2 EPS \$1.40 Beats \$0.72 Estimate, Sales \$153.302M Beat \$138.31M Estimate

Financial news for ACOR dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for ACOR dated on 2018-07-26: 50 Biggest Movers From Yesterday

Financial news for ACOR dated on 2018-07-25: UPDATE: Acorda, Alkermes v. Roxane Labs, Mylan, Teva Doc Shows 'On July 23, 2018, Acorda notified the court that "Acorda plans to seek an emergency injunction on July 25, 2018 absent a change in circumstances."'

Financial news for ACOR dated on 2018-07-25: Hearing Acorda Loses Bid For Emergency Order Blocking Ampyra Copy, Co. Is Awaiting Decision On Validity Of Ampyra Patents

Financial news for ACOR dated on 2018-07-13: 24 Stocks Moving In Friday's Mid-Day Session

Financial news for ACOR dated on 2018-06-30: The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus

Financial news for ACOR dated on 2018-06-11: 36 Biggest Movers From Friday

Financial news for ACOR dated on 2018-06-08: Hearing Jefferies Gives Mid-Day Comment On Acorda Following Ampyra Hearing: 2+ Years Of Ampyra Exclusivity Could Be Worth \$6/Share

Financial news for ACOR dated on 2018-06-08: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for ACOR dated on 2018-06-08: Upside In Acorda Being Attributed To Co. Appeal Hearing On Ampyra, Legal Dispute Research Firm MDC Financial Said Co. Did

'Exceptionally Well' On Its Oral Arguments During Hearing

Financial news for ACOR dated on 2018-05-30: Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immute Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Financial news for ACOR dated on 2018-05-29: Acorda Announces EMA Validation Of MAA Submission Of INBRIJA For Treatment Of OFF Symptoms In Parkinson's Patients

Financial news for ACOR dated on 2018-05-02: Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Financial news for ACOR dated on 2018-05-02: Acorda Q1 EPS \$(0.18) vs \$(0.41) In Prior Year pEriod, Sales \$106.16M Misses \$129M Est.

Financial news for ACOR dated on 2018-04-29: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Financial news for ACOR dated on 2018-03-26: Acorda Files Marketing Authorization Application for INBRIJA to the European Medicines Agency

Financial news for ACOR dated on 2018-02-28: Acorda Announces Agreement with Scopia Capital, Scopia to Appoint 2 Board Members

Financial news for ACOR dated on 2018-02-23: Pharma Stock Roundup: AstraZeneca, Merck, AbbVie And More

Financial news for ACOR dated on 2018-02-20: Acorda Announces FDA Acceptance of New Drug Application for INBRIJA

Financial news for ACOR dated on 2018-02-15: Leerink Partners Global Healthcare Conf. Concludes Today, Presenters Include: Synlogic, Quanterix, Acorda Therapeutics, Bristol-Myers, Alnylam, and HCA Healthcare

Financial news for ACOR dated on 2018-02-15: Acorda Therapeutics Sees FY18 AMPYRA Sales \$330M-\$350M

Financial news for ACOR dated on 2018-02-15: Acorda Therapeutics Reports Q4 EPS \$0.61 vs \$0.05 In Prior Year Period, Sales \$167.2M vs \$171M Est.

Financial news for ACOR dated on 2018-01-22: 34 Biggest Movers From Friday

Financial news for ACOR dated on 2018-01-19: 28 Stocks Moving In Friday's Mid-Day Session

Financial news for ACOR dated on 2018-01-19: 14 Stocks Moving In Friday's Pre-Market Session

Financial news for ACOR dated on 2018-01-19: Benzinga Pro's 6 Stocks To Watch Today

Financial news for ACOR dated on 2018-01-19: Acorda Therapeutics Shares Indicated Up 8.8% Premarket Fri. Following Renewed Takeover Chatter; Thurs. Stock Rallied As Much As ~7%, Only to Sell Off During Afternoon Session; Report Fri. Morning Suggests Biogen, UCB Are Interested

Financial news for ACOR dated on 2018-01-19: UPDATE: STAT's Feuerstein Tweets 'Amend that. There are other reasons an \$ACOR sale would be positive but Goodbye Ron is near the top.'

Financial news for ACOR dated on 2018-01-19: STAT News' Adam Feuerstein Tweets 'Sale of \$ACOR would be positive for no other reason than removing Ron Cohen from his CEO post. We'd all benefit from that.'

Financial news for ACOR dated on 2018-01-10: JP Morgan Healthcare Conference Continues Today, Presenters Include: Quidel, NovoCure, Acorda, PerkinElmer, Glaukos, IDEXX, MiMedx, Community Health, Global Blood Therapeutics, and Ultragenyx

Financial news for ACOR dated on 2018-01-08: Acorda Therapeutics Shares Down 4.46%; Earlier Co. Reported Prelim. Q4 Sales \$166M vs \$173.82M, FY17 Sales \$542M vs \$573.68M Est.; Co. Sees FY18 \$330-\$350M vs \$402.63M Est.

Financial news for ACOR dated on 2018-01-05: Acorda Therapeutics Exploring Sale, According to Reuters

Financial news for ACOR dated on 2017-12-15: Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More

Financial news for ACOR dated on 2017-12-07: Acorda Resubmits New Drug Application for INBRIJA

Financial news for ACOR dated on 2017-11-20: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for ACOR dated on 2017-11-20: Acorda Therapeutics Discontinues Development of Tozadenant

Financial news for ACOR dated on 2017-11-17: Acorda Therapeutics Announces \$53M of Payments for Royalty Rights

Financial news for ACOR dated on 2017-11-16: Benzinga's Top Upgrades, Downgrades For November 16, 2017

Financial news for ACOR dated on 2017-11-16: Stifel Nicolaus Downgrades Acorda Therapeutics to Hold

Financial news for ACOR dated on 2017-11-16: Raymond James Downgrades Acorda Therapeutics to Underperform

Financial news for ACOR dated on 2017-11-16: 40 Biggest Movers From Yesterday

Financial news for ACOR dated on 2017-11-15: Mid-Afternoon Market Update: OncoCyte Drops Following Q3 Results; Sorl Auto Parts Shares Jump

Financial news for ACOR dated on 2017-11-15: 33 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ACOR dated on 2017-11-15: Mid-Day Market Update: YY Climbs After Strong Q3 Results; SandRidge Energy Shares Plummet

Financial news for ACOR dated on 2017-11-15: UPDATE: Cowen Cuts Price Target On Acorda From \$35 To \$30, Maintains Outperform Rating

Financial news for ACOR dated on 2017-11-15: UPDATE: Cowen Sees Acorda's Inbrija As Undervalued

Financial news for ACOR dated on 2017-11-15: Cowen Issues Mid-Day Note On Acorda, Shares Down ~37%; Cowen Analyst Highlights 'We are skeptical a positive benefit-risk could be established, so we are removing Toz from our Acorda model'

Financial news for ACOR dated on 2017-11-15: Mid-Morning Market Update: Markets Open Lower; Target Profit Beats Estimates

Financial news for ACOR dated on 2017-11-15: Stifel 2017 Healthcare Conference Concludes Today, Presenters Include: Eleven Biotherapeutics, Clovis, Puma Biotechnology, Synlogic, KalVista Pharmaceuticals, Dicerna Pharmaceuticals, GTx, and Acorda Therapeutics

Financial news for ACOR dated on 2017-11-15: Acorda Therapeutics Shares Down 31% Upon Resumption

Financial news for ACOR dated on 2017-11-15: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ACOR dated on 2017-11-15: Acorda Therapeutics Shares To Resume Trade At 7:30 a.m. EST

Financial news for ACOR dated on 2017-11-15: UPDATE: Acorda To Discuss Update For Tozadenant Development Program On Call At 8:30 a.m. EST Wed.

Financial news for ACOR dated on 2017-11-15: UPDATE: Acorda Says 'paused new enrollment [for tozadenant] in the long-term safety studies, pending further discussion with the independent DSMB, FDA'

Financial news for ACOR dated on 2017-11-15: UPDATE: Acorda Says Co. Took Action 'in response to cases of agranulocytosis, possibly drug-related, and in some cases associated with sepsis and death'

Financial news for ACOR dated on 2017-11-15: UPDATE: Acorda On Tozadenant Development: Co. 'has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson's disease'

Financial news for ACOR dated on 2017-11-15: Acorda Offers Update On Toazdenant Development Program

Financial news for ACOR dated on 2017-11-15: BZ NOTE: Acorda Pres, CEO Ron Cohen To Present At Stifel's Healthcare Conference Wed., Nov. 15 At 10:45 a.m. EST

Financial news for ACOR dated on 2017-11-15: Acorda Shares Halted News Pending

Financial news for ACOR dated on 2017-11-14: 13F Filing From Baker Bros Shows Increased Stake In Acceleron Pharma, New Stake In Acorda Therapeutics

Financial news for ACOR dated on 2017-11-09: Oppenheimer Initiates Coverage On Acorda Therapeutics with Perform Rating, Announces \$27.00 Price Target

Financial news for ACOR dated on 2017-10-31: Acorda Sees FY17 AMPYRA Sales Of \$535-\$545M

Financial news for ACOR dated on 2017-10-31: Acorda Reports Q3 EPS \$0.43 vs \$0.65 Est., Sales \$141M vs \$150M Est.

Financial news for ACOR dated on 2017-09-27: Acorda Therapeutics Says it is Working with the FDA to Resubmit its Inbrija NDA

Financial news for ACOR dated on 2017-09-01: Acorda Adopts a Shareholder Rights Plan

Financial news for ACOR dated on 2017-08-31: 13D From Scopia Capital On Acorda Therapeutics Shows 18.2% Stake

Financial news for ACOR dated on 2017-08-30: Acorda Therapeutics Shares Move Higher With Other Stocks Over Last 10 Mins; Traders Attributing Move Higher To Positive Alert From Source On Agora Financial

Financial news for ACOR dated on 2017-08-29: Mid-Afternoon Market Update: U.S. Stocks Turn Higher; J.Jill Shares Plummet

Financial news for ACOR dated on 2017-08-29: 15 Biggest Mid-Day Losers For Tuesday

Financial news for ACOR dated on 2017-08-29: Mid-Day Market Update: Movado Rises After Strong Q2 Results; Finish Line Shares Slide

Financial news for ACOR dated on 2017-08-29: Mid-Morning Market Update: Markets Open Lower; Best Buy Tops Q2 Estimates

Financial news for ACOR dated on 2017-08-29: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ACOR dated on 2017-08-29: Adam Feuerstein Tweets: \$ACOR suffers embarrassing, costly delay to FDA review of Parkinson's drug
statnews.com/2017/08/29/aco... via @statnews

Financial news for ACOR dated on 2017-08-29: Acorda Receives Refusal to File Letter from FDA for INBRIJA Regarding its Previously Filed NDA

Financial news for ACOR dated on 2017-08-07: Activists Gonna Activate: Hedge Funds Send Letters To Acorda, Taubman Centers Boards

Financial news for ACOR dated on 2017-08-07: 18 Biggest Mid-Day Gainers For Monday

Financial news for ACOR dated on 2017-08-07: UPDATE: Acorda Says 'initiating a sale process or a public review of strategic alternatives at this point would destabilize operations, hinder our ability to execute...and risk significantly devaluing the Company'

Financial news for ACOR dated on 2017-08-07: UPDATE: Acorda Says 'We believe that a sale of the Company at the present time would not adequately compensate shareholders for the potential benefits of the Company's late-stage programs'

Financial news for ACOR dated on 2017-08-07: UPDATE: Acorda Says Board 'unanimously determined that focusing on our two late-stage programs in Parkinson's disease (INBRIJA(tm) and tozadenant) and maximizing AMPYRA is the best path forward...'

Financial news for ACOR dated on 2017-08-07: UPDATE: Acorda Says 'Board of Directors and management team are committed to acting in the best interests of shareholders and all Acorda stakeholders'

Financial news for ACOR dated on 2017-08-07: 8-K From Acorda Therapeutics Shows Response To Scopia Capital Mgmt.

Financial news for ACOR dated on 2017-08-07: Scopia Capital Has Submitted Letter To Acorda Board Uging Pursuit Of Strategic Alternatives, Including Sale of Co., Formation Of Special Committee

Financial news for ACOR dated on 2017-08-07: 13D From Scopia Capital On Acorda Therapeutics Shows 16.5% Stake

Financial news for ACOR dated on 2017-07-11: Jefferies Initiates Coverage On Acorda Therapeutics with Hold Rating, Announces \$22.00 Price Target

Financial news for ACOR dated on 2017-06-29: Acorda Submits NDA To FDA For INBRIJATM

Financial news for ACOR dated on 2017-06-20: Acorda Therapeutics CEO Ron Cohen Buys 20,000 @ Avg Price: \$16.95 -Form4

Financial news for ACOR dated on 2017-06-09: Acorda Therapeutics Says it Filed an Appeal for 4 Invalidated Patents

Financial news for ACOR dated on 2017-06-06: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ACOR dated on 2017-06-05: Acorda Therapeutics Offers Phase 3 Data for CVT-301 Showing Significantly Improved Motor Function During OFF Periods in Parkinson's Disease

Financial news for ACOR dated on 2017-04-27: Adam Feuerstein Tweets: \$ACOR call --Stifel analyst Tom Schrader apologized to management. "Sorry for how this all turned out, but that's the business." Vomit.

Financial news for ACOR dated on 2017-04-27: Acorda Q1 EPS \$(0.08) vs \$0.09 Est, Sales \$119.39M vs \$127.34M Est

Financial news for ACOR dated on 2017-04-05: Acorda Therapeutics to Cut Headcount by 20%

Financial news for ACOR dated on 2017-04-03: 12 Biggest Mid-Day Losers For Monday

Financial news for ACOR dated on 2017-04-03: Acorda Therapeutics Down 4.76% Premarket Following Downgrades From JPMorgan and Janney

Financial news for ACOR dated on 2017-04-03: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for ACOR dated on 2017-03-31: Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher

Financial news for ACOR dated on 2017-03-31: Acorda Therapeutics Shares Resume Trade, Down 23.27%

Financial news for ACOR dated on 2017-03-31: Acorda Therapeutics Shares to Resume Trade at 1 p.m. EDT

Financial news for ACOR dated on 2017-03-31: Acorda Issues Press Release Confirming US District Court Decision to Invalidate 4 AMPYRA Patents, Says Co. Will Appeal Ruling

Financial news for ACOR dated on 2017-03-31: Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient

Financial news for ACOR dated on 2017-03-31: Acorda Halted News Pending

Financial news for ACOR dated on 2017-03-31: Forward Pharma Shares Resume, Continue Lower, Now Down 32%

Financial news for ACOR dated on 2017-03-31: Acorda Shares Resume, Plunge Lower, Now Down 26%; Halted on Second Circuit Breaker

Financial news for ACOR dated on 2017-03-31: Forward Pharma Shares Plunge 14%, Halted on Circuit Breaker, Likely on the Heels of Acorda News, Move

Financial news for ACOR dated on 2017-03-31: UPDATE: Acorda Shares Halted on Circuit Breaker, Down 14%

Financial news for ACOR dated on 2017-03-31: Adam Feuerstein Tweets: \$ACOR "District Court finds all four Acorda Ampyra patents invalid for obviousness -- filing" per StreetAccount.

Financial news for ACOR dated on 2017-03-31: Adam Feuerstein @adamfeuerstein now \$ACOR "District Court finds all four Acorda Ampyra patents invalid for obviousness -- filing" per StreetAccount

Financial news for ACOR dated on 2017-03-31: Acorda Therapeutics Falls to Low of \$22.85; Halted on CB

Financial news for ACOR dated on 2017-03-29: Acorda Therapeutics Spikes to High of \$29.75 on Volume

Financial news for ACOR dated on 2017-03-29: Acorda Therapeutics Study Shows

Participants Receiving CVT-301 Had No Change in Pulmonary Function vs the Control Group

Financial news for ACOR dated on 2017-03-13: 8 Biggest Price Target Changes For Monday

Financial news for ACOR dated on 2017-03-13: Benzinga's Top Upgrades, Downgrades For March 13, 2017

Financial news for ACOR dated on 2017-03-13: Janney Capital Upgrades Acorda Therapeutics To Buy, Raises Price Target To \$38

Financial news for ACOR dated on 2017-03-09: Acorda Therapeutics Higher Off Favorable Patent Ruling Related To Ampyra

Financial news for ACOR dated on 2017-03-09: Acorda Press Release Confirms PTAB Upheld Four AMPYRA Patents

Financial news for ACOR dated on 2017-03-09: Acorda Shares Resume Trade, Continue Higher, Now Up 7.4%

Financial news for ACOR dated on 2017-03-09: Traders Attributing Move Higher in Acorda to Patent Ruling Related to Ampyra

Financial news for ACOR dated on 2017-03-09: Acorda Therapeutics Shares Halted on Circuit Breaker, Now Up ~7%

Financial news for ACOR dated on 2017-03-09: Acorda Therapeutics Shares Up \$2+ Over Last Min.

Financial news for ACOR dated on 2017-03-06: Watch These 7 Huge Put Purchases In Monday Trade

Financial news for ACOR dated on 2017-03-03: Benzinga's Option Alert Recap From March 3

Financial news for ACOR dated on 2017-03-03: Option Alert: Accorda Therapeutics Mar 24.0 Puts Sweep: 1614 @ ASK \$2.40: 2709 traded vs 361 OI: Earnings 4/27 Before Open (est) \$27.20 Ref

Financial news for ACOR dated on 2017-02-15: Benzinga's Top Upgrades, Downgrades For February 15, 2017

Financial news for ACOR dated on 2017-02-15: Goldman Sachs Upgrades Acorda Therapeutics To Neutral

Financial news for ACOR dated on 2017-02-14: Acorda Therapeutics Q4 EPS \$0.05 vs \$0.11 Est, Revenue \$132M vs \$137.9M Est

Financial news for ACOR dated on 2017-02-14: Earnings Scheduled For February 14, 2017

Financial news for ACOR dated on 2017-02-10: Watch These 5 Huge Put Purchases In Friday Trade

Financial news for ACOR dated on 2017-02-09: Benzinga's Option Alert Recap From February 9

Financial news for ACOR dated on 2017-02-09: Option Alert: Acorda Mar \$20 Put; 6800 @Bid @\$3.20

Financial news for ACOR dated on 2017-02-09: Acorda Therapeutics Reports SPAN-PD Trial for CVT-301 Met Primary Endpoint, Showing Statistical Significant Improvement of Motor Function; Sees NDA Submission Q2

Financial news for ACOR dated on 2017-01-09: Acorda Q4 AMPYRA Sales \$132M, Sees FY 2017 AMPYRA Sales \$535M to \$545M

Financial news for ACOR dated on 2016-12-30: January Will Feature Some Of The Market's Most Influential Events

Financial news for ACOR dated on 2016-12-19: 12 Biggest Mid-Day Losers For Monday

Financial news for ACOR dated on 2016-12-19: Benzinga's Top Upgrades, Downgrades For December 19, 2016

Financial news for ACOR dated on 2016-12-19: Janney Capital Initiates Coverage On Acorda Therapeutics at Neutral, Announces \$23.00 Target

Financial news for ACOR dated on 2016-12-16: Cantor Fitzgerald Initiates Coverage On

Acorda Therapeutics at Neutral, Announces \$21.00 Target

Financial news for ACOR dated on 2016-11-21: Mid-Day Market Update: Headwaters Surges On Acquisition News; Cubic Shares Slide

Financial news for ACOR dated on 2016-11-21: Mid-Morning Market Update: Markets Open Higher; Symantec To Acquire Lifelock

Financial news for ACOR dated on 2016-11-21: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for ACOR dated on 2016-11-21: Acorda Therapeutics to Discontinue Development of Dalfampridine for Treatment of Post-Stroke Walking Difficulties

Financial news for ACOR dated on 2016-11-16: Stifel Healthcare Conference Continues Today

Financial news for ACOR dated on 2016-10-27: Acordia Q3 EPS \$(0.04) vs \$0.11 Est, Revenue \$135.6M vs \$134.0M Est

Financial news for ACOR dated on 2016-10-27: Acorda Sees Q3 AMPYRA Net Revenue \$128.8M to \$117.0M

Financial news for ACOR dated on 2016-10-13: Acordia Reports Data Published In Science Translational Medicine For CVT-301 For Parkinson's Treatment

Financial news for ACOR dated on 2016-10-04: Leerink Swann Assumes Acorda Therapeutics at Market Perform

Financial news for ACOR dated on 2016-10-04: Acorda CFO Leaves Company

Financial news for ACOR dated on 2016-09-29: Stocks Hitting 52-Week Lows

Financial news for ACOR dated on 2016-09-26: Monday Market Wrap: Stocks Fall Nearly 1% To Start Week

Financial news for ACOR dated on 2016-09-26: Mid-Afternoon Market Update: Dow Falls 150 Points; Himax Technologies Shares Slide After Nomura Downgrade

Financial news for ACOR dated on 2016-09-26: Mid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News

Financial news for ACOR dated on 2016-09-26: The Street's Adam Feuerstein Tweets: \$ACOR down bc last week's court hearings on Ampyra patent challenge didn't go well. Increased chance of generic launch in 2018.

Financial news for ACOR dated on 2016-09-26: Mid-Morning Market Update: Markets Open Lower; Cal-Maine Posts Wider-Than-Expected Loss

Financial news for ACOR dated on 2016-08-25: Option Alert: Acorda Therapeutics Jan 20 \$23 Puts at the bid: 500 @ 3.05 vs. Open Interest 0

Financial news for ACOR dated on 2016-08-15: Acorda Therapeutics Enters Settlement Agreement with Accord Healthcare, Intas Pharma Over Ampyra

Financial news for ACOR dated on 2016-08-03: 8-K from Acorda Therapeutics Shows Settlement Deal with Alkem Labs, Ascend Labs for Resolving Patent Litigation Related to Ampyra ER Tablets

Financial news for ACOR dated on 2016-07-28: Acorda Raises FY16 Adj. EPS Outlook from \$3.39-\$3.49 to \$3.43-\$3.53

Financial news for ACOR dated on 2016-07-28: Acorda Reaffirms FY16 AMPYRA Sales \$475M-\$485M

Financial news for ACOR dated on 2016-07-28: Acorda Reports Q2 Adj. EPS \$0.07 vs \$0.31 in Same Qtr. Last Year, Sales \$127.458M vs \$113.7M YoY

Financial news for ACOR dated on 2016-07-01: Acorda Names Dr. Burkhard Blank Chief Medical Officer

Financial news for ACOR dated on 2016-06-21: Hearing Acorda Therapeutics Has Said US Appeals Court Denied Mylan's Request for Rehearing in Ampyra Case

Financial news for ACOR dated on 2016-06-21: US Court of Appeals for Federal Circuit Denied Request by Mylan for Rehearing of Court's Previous Decision to Uphold Lower Court Ruling that Acorda's ANDA Litigation vs Mylan can Continue in District Court of Delaware

Financial news for ACOR dated on 2016-06-02: Acorda Therapeutics Enters into Credit Agreement With JPMorgan Chase Bank

Financial news for ACOR dated on 2016-05-20: Acorda Dips 2%, Company Says It Will Discontinue Development Of Nasal Spray

Financial news for ACOR dated on 2016-05-20: Acorda to Discontinue of PLUMIAZ for Treatment of Epilepsy Seizure Clusters

Financial news for ACOR dated on 2016-05-20: Acorda to Discontinue Development of PLUMIAZ for Treatment of Epilepsy Seizure Clusters

Financial news for ACOR dated on 2016-05-18: Biotie Therapies to Delist US Listing

Financial news for ACOR dated on 2016-05-18: Biotie Therapies Cancels All Treasury Shares Held by Company

Financial news for ACOR dated on 2016-05-18: Biotie Therapies to Delist ADS from Nasdaq Global Select Market

Financial news for ACOR dated on 2016-05-16: Acorda Sells Off to Low of \$26.02 on Vol

Financial news for ACOR dated on 2016-04-28: Acorda Q1 EPS \$0.07 vs \$0.08 est, Revenue \$109.6M vs \$115.4M est

Financial news for ACOR dated on 2016-04-25: Acorda Reports 93.9% Stake in Biotie Therapies in 13D

Financial news for ACOR dated on 2016-04-20: Acorda Therapeutics Sees Improvements In Phase 2b Clinical Study Of CVT301

Financial news for ACOR dated on 2016-04-20: Acorda Reports Results from Phase 2b Clinical Trial of CVT-301 for Treatment of OFF Periods in Parkinson's Disease Published in Movement Disorders , Showed Significantly Greater Improvement In Motor Function vs. Placebo

Financial news for ACOR dated on 2016-04-13: Accorda Therapeutics Announces Final Results Of Tender Offer On Biotie Therapies

Financial news for ACOR dated on 2016-04-07: Phase 2b Data on Inhaled Levodopa CVT-301 Featured in Invited Science Session at American Academy of Neurology Annual Meeting

Financial news for ACOR dated on 2016-03-30: Goldman On Biotech: Buy Sage, Sell Acorda, Neutral On Dimension

Financial news for ACOR dated on 2016-03-30: Goldman Sachs Initiates Coverage on Acorda Therapeutics at Neutral, Announces \$23.00 PT

Financial news for ACOR dated on 2016-03-29: Acorda Therapeutics Says it has Completed Phase 1 Single-dose Pharmacokinetic studies for Three Separate Once-daily Formulations of Dalfampridine

Financial news for ACOR dated on 2016-03-23: What's Going On With Kyle Bass And Biogen?

Financial news for ACOR dated on 2016-03-21: Acorda Therapeutics Announces Federal Court Upheld Ruling Against Mylan that NDA Can Continue

Financial news for ACOR dated on 2016-03-11: Acorda Announces Patent Trials and Appeal Board (PTAB) Institutes IPRs of AMPYRA Patents

Financial news for ACOR dated on 2016-03-11: Hearing Kyle Bass Coalition IPR Review Instituted against Challenged Acorda '703 Ampyra Patent

Financial news for ACOR dated on 2016-03-11: Acorda Therapeutics Sells Off to Low of \$34.26 on Volume

Financial news for ACOR dated on 2016-03-10: Acorda Therapeutics Announces Will Begin Voluntary Public Tender Offer for All of Issued, Outstanding Shares, ADS, Options, Units, Warrants in Biotie Therapies Corp. on Mar. 11, '16

Financial news for ACOR dated on 2016-03-08: Acorda Therapeutics Announces Update on its Program to Develop CVT-427 as Acute Treatment for Migraine using ARCUS Inhaled Delivery Technology

Financial news for ACOR dated on 2016-03-03: Acorda Files Tender Offer Document Relating to Public Tender Offer for Biotie Therapies with Finnish Financial Supervisory Authority

Financial news for ACOR dated on 2016-03-01: Stocks To Watch During Cowen's 36th Annual Healthcare Conference

Financial news for ACOR dated on 2016-02-11: Acorda Therapeutics Sees FY Revenue \$475M to \$485M vs \$516M est

Financial news for ACOR dated on 2016-02-11: Acorda Therapeutics Q4 EPS \$0.28 vs \$0.22 est, Revenue \$122M vs \$128M est

Financial news for ACOR dated on 2016-01-25: 8-K Filing Shows Acorda Therapeutics To Offer 2,250,900 Shares To Initial Purchaser In Private Placement

Financial news for ACOR dated on 2016-01-21: Acorda Therapeutics Confirms It Entered Into A Patent Litigation Settlement Deal With Par Pharma

Financial news for ACOR dated on 2016-01-20: 8-K from Acorda Therapeutics Shows Co. Entered Settlement Deal with Par Pharma Related to Pending Patent Litigation Related to Ampyra ER Tablets

Financial news for ACOR dated on 2016-01-19: Benzinga's M&A Chatter for Tuesday January 19, 2015

Financial news for ACOR dated on 2016-01-19: Mid-Afternoon Market Update: US Stocks Turn Red; Crude Oil Falls Over 3%

Financial news for ACOR dated on 2016-01-19: Mid-Day Market Update: Dow Surges 150 Points; Progressive Waste Shares Spike Higher

Financial news for ACOR dated on 2016-01-19: Mid-Morning Market Update: Markets Open Higher; Bank of America Earnings Top Views

Financial news for ACOR dated on 2016-01-19: Acorda Therapeutics To Acquire Biotie Therapies To Boost Its Parkinson's Disease Therapeutic Development

Financial news for ACOR dated on 2016-01-19: Acorda to Acquire Biotie Therapies for \$25.60/ADS

Financial news for ACOR dated on 2016-01-11: Acorda Therapeutics Sees FY2016 Sales \$475.0M-485.0M vs \$518.40M Est

Financial news for ACOR dated on 2016-01-06: Aegis Capital Maintains Buy on Acorda Therapeutics, Raises PT to \$52.00

Financial news for ACOR dated on 2016-01-02: Kyle Bass Explains The 'Patent Trolls' Situation In The Pharma Industry

Financial news for ACOR dated on 2015-12-10: 8-K from Acorda Therapeutics Shows Co. Entered Settlement Deal with Aurobindo Pharma to Resolve Pending Patent Litigation

Financial news for ACOR dated on 2015-12-03: Acorda Starts Phase 1 Clinical Trial of CVT-427, Inhaled Therapy for Acute Treatment of Migraines

Financial news for ACOR dated on 2015-10-22: Acorda Therapeutics Q3 EPS \$0.31 vs \$0.15 est, Revenue \$117M vs \$115.5M est

Financial news for ACOR dated on 2015-10-21: 8-K from Acorda Therapeutics Shows Settlement Deal with Sun Pharma Related to Patent Litigation

Financial news for ACOR dated on 2015-10-07: Acorda to Present New rHIgM22 and AMPYRA Data at 31st Congress of European Committee for Treatment and Research in MS

Financial news for ACOR dated on 2015-10-05: Benzinga's Volume Movers

Financial news for ACOR dated on 2015-10-05: Acorda Therapeutics 8-K Says Co. Agrees With Actavis to Resolve Pending Patent Litigation

Financial news for ACOR dated on 2015-09-03: Acorda Therapeutics 8-K Filing Shows Company Will Oppose Requests To Institute For IPRS, Will Oppose Full Proceedings And Defend Patents

Financial news for ACOR dated on 2015-08-26: Benzinga's Top #PreMarket Gainers

Financial news for ACOR dated on 2015-08-25: Mid-Morning Market Update: Markets Open Higher; Best Buy Tops Q2 Views

Financial news for ACOR dated on 2015-08-25: Benzinga's Volume Movers

Financial news for ACOR dated on 2015-08-25: Morning Market Gainers

Financial news for ACOR dated on 2015-08-25: Benzinga's Top #PreMarket Gainers

Financial news for ACOR dated on 2015-08-24: Acorda Reports Patent Trials and Appeal Board (PTAB) Denies Both IPRs of AMPYRA Patents

Financial news for ACOR dated on 2015-08-24: Evercore ISI's Mark Schoenebaum Comments on Acorda Following ADROCA Filing: Highlights Patent Trial and Appeal Board of USPTO Ruled Not to Institute Two Intellectual Property Rights on Co.'s Ampyra

Financial news for ACOR dated on 2015-08-24: Acorda Therapeutics Indicated Up 12% After Hours On News That Kyle Bass Denied Intellectual Property Rights Patent Number'685

Financial news for ACOR dated on 2015-06-24: Acorda Data on Inhaled Levodopa Therapy CVT-301 Recognized at International Congress of Parkinson's Disease and Movement Disorders

Financial news for ACOR dated on 2015-06-19: Biotech Stocks Worth Taking A Look At

Financial news for ACOR dated on 2015-06-16: Acorda Reports Data Inhaled Levodopa Therapy CVT-301 at International Congress of Parkinson's Disease and Movement Disorders

Financial news for ACOR dated on 2015-06-09: Guggenheim Securities Initiates Coverage on Acorda Therapeutics at Neutral

Financial news for ACOR dated on 2015-06-02: Morning Market Losers

Financial news for ACOR dated on 2015-06-02: Acorda Therapeutics Shares Fall 9% Premarket Following Report of Clinical Hold

Financial news for ACOR dated on 2015-06-02: UPDATE 8K Filing: Acorda Therapeutics Puts Hold On 1B Clinical Trail Of Cimaglermin Alfa Based On Hepatotoxicity Occurrence

Financial news for ACOR dated on 2015-06-02: Acorda Therapeutics Puts Hold On 1B Clinical Trail Of Cimaglermin Alfa Based On Hepatotoxicity Occurrence

Financial news for ACOR dated on 2015-04-30: Acorda Q1 EPS \$0.15 vs \$0.14 est

Financial news for ACOR dated on 2015-04-22: Piper Jaffray Assumes Acorda Therapeutics at Neutral

Financial news for ACOR dated on 2015-04-22: Acorda Presents Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting

Financial news for ACOR dated on 2015-04-22: Acorda Reports Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting

Financial news for ACOR dated on 2015-04-20: Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent

Financial news for ACOR dated on 2015-03-11: 18 Biotech Stocks These Wall Street Analysts Are Tracking

Financial news for ACOR dated on 2015-02-27: Second IPR from Kyle Bass on Acorda

Financial news for ACOR dated on 2015-02-17: This Analyst Is Defending Acorda Therapeutics; Shares Still Down 7% In A Week

Financial news for ACOR dated on 2015-02-12: Benzinga's Top Initiations

Financial news for ACOR dated on 2015-02-12: MLV & Co. Initiates Acorda Therapeutics With Buy

Financial news for ACOR dated on 2015-02-12: MLV & Co. Initiates Coverage on Acorda Therapeutics at Buy, Announces \$58.00 PT

Financial news for ACOR dated on 2015-02-12: Acorda Therapeutics Q4 EPS \$0.46 vs \$0.49, Sales \$117.9M vs \$118.4M

Financial news for ACOR dated on 2015-02-12: Earnings Scheduled For February 12, 2015

Financial news for ACOR dated on 2015-02-11: Stifel Says Acorda Therapeutics Decline Is 'A Buying Opportunity'

Financial news for ACOR dated on 2015-02-10: Acorda Therapeutics Spikes Higher; Court

Filing Being Circulated

Financial news for ACOR dated on 2015-02-02: Gilead Could Miss Earnings (Hint: Watch Drug Sales)

Financial news for ACOR dated on 2015-02-02: Acorda Announces Positive Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis

Financial news for ACOR dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for ACOR dated on 2015-01-12: Acorda Therapeutics Says Deferring Further Development of NP-1998 for Neuropathic Pain in 2015

Financial news for ACOR dated on 2015-01-12: Acorda Therapeutics Sees FY2015 Sales \$405.0M-420.0M vs \$413.07M Est

Financial news for ACOR dated on 2015-01-06: J.P Morgan Just Chimed In With Ratings On Biotech Stocks

Financial news for ACOR dated on 2014-12-15: US Stock Futures Up Ahead Of Economic Data

Financial news for ACOR dated on 2014-12-15: Acorda Initiates Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits

Financial news for ACOR dated on 2014-12-05: Benzinga's Top Initiations

Financial news for ACOR dated on 2014-12-05: Goldman Sachs Initiates Acorda Therapeutics With Neutral

Financial news for ACOR dated on 2014-12-05: Goldman Sachs Initiates Coverage on Acorda Therapeutics, Inc. at Neutral, Announces \$40.00 PT

Financial news for ACOR dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for ACOR dated on 2014-11-06: 8 Attractive U.S. Healthcare Stocks With Low PEG Ratios

Financial news for ACOR dated on 2014-10-30: Acorda Therapeutics, Inc. Reports Q3 EPS of \$0.28 vs \$0.05 Est; Revenue of \$106.0M vs \$94.56M Est

Financial news for ACOR dated on 2014-10-02: Acorda Shares Move Higher After-Hours on CEO Appearance on Mad Money with Jim Cramer

Financial news for ACOR dated on 2014-10-02: Acorda Shares Move Higher; Will Appear on Mad Money Tonight with Jim Cramer

Financial news for ACOR dated on 2014-09-24: Benzinga's M&A Chatter for Wednesday September 24, 2014

Financial news for ACOR dated on 2014-09-24: Stocks Gain While Dollar Reaches Highest Level Since 2010

Financial news for ACOR dated on 2014-09-24: Dow Jumps 170 Points; Bed Bath & Beyond Shares Rise On Upbeat Results

Financial news for ACOR dated on 2014-09-24: Shares of Acorda Edge to Fresh Session Highs as Cowen Has Just Issued Mid-Day Note Boosting Price Target from \$52 to \$65

Financial news for ACOR dated on 2014-09-24: U.S. Stocks Rise; Accenture Shares Decline On Weak Forecast

Financial news for ACOR dated on 2014-09-24: Markets Edge Lower; KB Home Posts Downbeat Results

Financial news for ACOR dated on 2014-09-24: Benzinga's Volume Movers

Financial news for ACOR dated on 2014-09-24: Morning Market Movers

Financial news for ACOR dated on 2014-09-24: Shares of Acorda Trading Up ~7%

Financial news for ACOR dated on 2014-09-24: Shares of Acorda Therapeutics to Resume Trade at 7:55 a.m. EDT

Financial news for ACOR dated on 2014-09-24: UPDATE: Acorda Will Receive Rights to Phase 3 Parkinson's Disease Treatment

Financial news for ACOR dated on 2014-09-24: Acorda to Purchase Civitas Therapeutics

for \$525M

Financial news for ACOR dated on 2014-09-24: Shares of Acorda Therapeutics Halted News Pending

Financial news for ACOR dated on 2014-09-10: Events for the Week of Sept. 8-12

Financial news for ACOR dated on 2014-08-12: Shares of Acorda Therapeutics Quiet Following FBR Note Suggesting Co.'s Evaluation of Five Options Could Create Situation Allowing for Inversion Strategy

Financial news for ACOR dated on 2014-07-31: Acorda Therapeutics Reports Q2 Adjusted EPS of \$0.42 Which May Not Compare \$0.15 Est; Revenue of \$87.40M Which May Not Compare \$91.42M Est

Financial news for ACOR dated on 2014-07-10: Watch Acorda Shares as Pres, CEO Ron Cohen Currently Talking on CNBC

Financial news for ACOR dated on 2014-07-09: Markets Edge Higher; Alcoa Profit Beats Street View

Financial news for ACOR dated on 2014-07-09: Acorda Therapeutics Says Expects to Initiate Phase 3 Clinical Trial Studying Use of Dalfampridine by Year's End -8-K

Financial news for ACOR dated on 2014-06-26: Acorda Therapeutics Announces Notification Of ANDA Filing For AMPYRA

Financial news for ACOR dated on 2014-06-18: Benzinga's Volume Movers

Financial news for ACOR dated on 2014-06-17: Market Wrap For June 17: Markets Higher Ahead Of Fed Decision

Financial news for ACOR dated on 2014-06-17: Mid-Afternoon Market Update: Oil Falls, US Indexes Rise In Afternoon Session

Financial news for ACOR dated on 2014-06-17: Mid-Day Market Update: Amira Rises On Upbeat Earnings; Acorda Therapeutics Shares Tumble

Financial news for ACOR dated on 2014-06-17: Mid-Morning Market Update: Markets Gain; FactSet Posts Rise In Revenue

Financial news for ACOR dated on 2014-06-17: Morning Market Losers

Financial news for ACOR dated on 2014-06-16: Filing from Acorda Therapeutics Shows Automatic Mixed Securities Shelf

Financial news for ACOR dated on 2014-05-06: Acorda Therapeutics Reports Q1 EPS of \$0.02 vs \$0.10 Est; Revenue of \$72.50M vs \$81.28M Est

Financial news for ACOR dated on 2014-05-02: Acorda Therapeutics Announces FDA CRL for PLUMIAZ NDA

Financial news for ACOR dated on 2014-04-17: Canaccord Genuity Initiates Coverage on Acorda Therapeutics, Inc. at Hold, Announces \$37.00 PT

Financial news for ACOR dated on 2014-04-14: FBR Capital Upgrades Acorda Therapeutics, Inc. to Outperform, Raises PT to \$47.00

Financial news for ACOR dated on 2014-04-14: Acorda to Initiate Phase 3 Study of Dalfampridine-QD In People With Post-Stroke Walking Deficits in H2 2014

Financial news for ACOR dated on 2014-02-13: Acorda Therapeutics Reports Q4 EPS of \$0.15, Inline; Revenue of \$92.60M vs \$90.78M Est

Financial news for ACOR dated on 2014-01-06: Citigroup downgraded Acorda Therapeutics, Says Fundamentals Have Reversed For the Near-Term

Financial news for ACOR dated on 2014-01-06: Citigroup Downgrades Acorda Therapeutics, Inc. to Neutral, Lowers PT to \$33.00

Financial news for ACOR dated on 2013-12-19: Acorda Therapeutics Announces European Patent Office Upholds Fampridine Patent

Financial news for ACOR dated on 2013-12-09: Acorda Presents New Diazepam Nasal Spray Data at 67th Annual Meeting of American Epilepsy Society

Financial news for ACOR dated on 2013-11-05: Acorda Shares Spike Higher During CEO Appearance with Jim Cramer on Mad Money

Financial news for ACOR dated on 2013-11-01: MKM Partners Upgrades Acorda Therapeutics, Inc. to Neutral

Financial news for ACOR dated on 2013-10-31: Acorda Therapeutics Reports Q3 Adjusted EPS of \$0.38 vs \$0.13 Est; Revenue of \$84.92M vs \$90.01M Est

Financial news for ACOR dated on 2013-10-14: Acorda Therapeutics Reports Data from Phase 2 Trial of Delfampridine-ER, Says Data Consistent with Prior Trials

Financial news for ACOR dated on 2013-10-07: Acorda Therapeutics Names Michael Rogers CFO

Financial news for ACOR dated on 2013-08-01: Acorda Therapeutics, Inc. Reports Q2 Adjusted EPS of \$0.25 vs \$0.09 Est; Revenue of \$87.10M vs \$82.57M Est

Financial news for ACOR dated on 2013-06-26: First Study of Diazepam Nasal Spray in People with Epilepsy Shows Feasibility of Dosing During Seizure

Financial news for ACOR dated on 2013-05-20: Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA(R) Covering a Range of Dosage Strengths

Financial news for ACOR dated on 2013-05-20: Acorda Therapeutics Announces New US Patent for AMPYRA

Financial news for ACOR dated on 2013-05-02: MKM Partners Downgrades Acorda Therapeutics, Inc. to Sell

Financial news for ACOR dated on 2013-05-02: Acorda Therapeutics, Inc. Reports Q1 EPS of \$0.09 vs \$0.13 Est; Revenue of \$71.90M vs \$80.71M Est

Financial news for ACOR dated on 2013-04-17: Acorda Therapeutics Spikes Higher

Financial news for ACOR dated on 2013-04-16: Market Wrap for Tuesday, April 16: Stock Market Rebounds Strongly From Monday's Sharp Losses

Financial news for ACOR dated on 2013-04-15: Market Wrap for Monday, April 15: Major Sell-Off Sweeps Wall Street; Gold Plunges to 2-Year Low

Financial news for ACOR dated on 2013-04-15: Mid-Afternoon Market Update: Explosions Rock Downtown Boston, Authorities Unsure if Explosive Devices

Financial news for ACOR dated on 2013-04-15: Mid-Day Market Update: Sprint Surges On Dish Network Offer, AuRico Gold Tumbles

Financial news for ACOR dated on 2013-04-15: Stocks Hitting 52-Week Highs

Financial news for ACOR dated on 2013-04-15: Acorda Therapeutics Announces Positive AMPYRA Phase 2 Data in People with Post-Stroke Deficits

Financial news for ACOR dated on 2013-03-07: Acorda Says FDA Granted Fast Track Designation for GFF2

Financial news for ACOR dated on 2013-02-13: Acorda Therapeutics, Inc. Reports Q4 EPS of \$0.24 vs \$0.15 Est; Revenue of \$81.47M vs \$78.90M Est

Financial news for ACOR dated on 2013-02-04: Acorda Therapeutics Could Be a Stock to Watch in 2013

Financial news for ACOR dated on 2013-01-11: Editor of Little Bear Blog is Long Acorda Therapeutics

Financial news for ACOR dated on 2013-01-09: Acor CEO Cohen: 'Over 70,000 People with MS have Tried Ampyra'

Financial news for ACOR dated on 2013-01-09: Acor CEO Cohen: 'Investing in Economical Medications is the Better Way to Go'

Financial news for ACOR dated on 2013-01-09: Acor CEO Cohen: 'Physical Therapy is Useful for People Who have had Strokes, But Not the Same as Medication'

Financial news for ACOR dated on 2013-01-09: Jim Cramer Interviews CEO Ron Cohen of Acor Therapeutics on Mad Money

Financial news for ACOR dated on 2013-01-08: From Earlier: MKM Partners Downgrades Acorda Therapeutics, Inc. to Neutral

Financial news for ACOR dated on 2013-01-07: UPDATE: Acorda Sees 2013 Other Sales ~\$25M (Fampyra, Zanaflex)

Financial news for ACOR dated on 2013-01-07: Acorda Therapeutics Sees 2013 Ampyra US Net Sales \$285-315M

Financial news for ACOR dated on 2013-01-03: UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts

Financial news for ACOR dated on 2013-01-03: Citigroup Upgrades Acorda Therapeutics, Inc. to Buy, Raises PT to \$33.00

Financial news for ACOR dated on 2012-12-21: A Peek Into The Market Before The Trading Starts

Financial news for ACOR dated on 2012-12-21: Acorda Therapeutics Completes Neuronex Acquisition

Financial news for ACOR dated on 2012-11-05: Aegis Capital Maintains Acorda Therapeutics at Buy, Raises PT from \$32 to \$34

Financial news for ACOR dated on 2012-10-31: Acorda Therapeutics Reports Q3 EPS \$0.38 vs \$0.10 Est; Revenues \$77.4M vs \$75.20M Est

Financial news for ACOR dated on 2012-10-24: Acorda Spikes Lower

Financial news for ACOR dated on 2012-10-12: Acorda Therapeutics Spikes Higher

Financial news for ACOR dated on 2012-10-09: Acorda Therapeutics Names Jane Wasman President, International

Financial news for ACOR dated on 2012-10-08: Acorda Therapeutics Falls 4%; Hearing Group Health Negative Report on Ampyra

Financial news for ACOR dated on 2012-08-28: Acorda Therapeutics Announces GGF2 Preclinical Data on Treatment of Erectile Dysfunction

Financial news for ACOR dated on 2012-08-21: UPDATE: Aegis Capital Corp Initiates Buy on Acorda Therapeutics on Ampyra Visibility

Financial news for ACOR dated on 2012-08-21: Aegis Capital Initiates Coverage on Acorda Therapeutics at Buy, Announces PT of \$32

Financial news for ACOR dated on 2012-08-13: Benzinga's Top Pre-Market Gainers

Financial news for ACOR dated on 2012-08-02: Option Alert: Acorda Therapeutics Call Volume at 1,678% of Average; Currently \$22.61

Financial news for ACOR dated on 2012-07-31: Acorda Therapeutics Reports Q2 EPS \$0.27 vs \$0.12 Est; Revenues \$75.7M vs \$72.55M Est

Financial news for ACOR dated on 2012-07-23: FDA Warns of Seizure Risk in MS Patients Taking Acorda's Ampyra

Financial news for ACOR dated on 2012-07-23: Leerink Swann Resumes Coverage on Acorda Therapeutics at Outperform

Financial news for ACOR dated on 2012-06-19: Acorda CEO Cohen: 'Our Challenge Going Forward is to Make Sure Enough People with MS Know about Our Drug'

Financial news for ACOR dated on 2012-06-19: Acorda CEO Cohen: 'We Project We Will See Between \$225M and \$275M in Sales This Year for Ampyra'

Financial news for ACOR dated on 2012-06-19: Acorda CEO Cohen: 'There are a Lot of People with MS Who Have Not Tried Ampyra'

Financial news for ACOR dated on 2012-06-19: Jim Cramer Interviews CEO Dr. Ron Cohen of Acorda Therapeutics on Mad Money

Financial news for ACOR dated on 2012-06-12: From Earlier: Acorda Therapeutics Announces Initiation of AMPYRA(r) Proof-of-Concept Study in Patients with Post-Stroke Deficits

Financial news for ACOR dated on 2012-06-12: A Peek Into The Market Before The Trading Starts

Financial news for ACOR dated on 2012-06-12: Acorda Therapeutics Announces Initiation of AMPYRA(r) Proof-of-Concept Study in Patients with Post-Stroke Deficits

Financial news for ACOR dated on 2012-06-11: Appeals Court Upholds Patent Decision Against Acorda Therapeutics -Bloomberg

Financial news for ACOR dated on 2012-05-18: UPDATE: Goldman Sachs Initiates Sell on Acorda Therapeutics; Ampyra Risk

Financial news for ACOR dated on 2012-05-18: Goldman Sachs Initiates Coverage on Acorda Therapeutics at Sell, Announces PT of \$21

Financial news for ACOR dated on 2012-05-03: Acorda Therapeutics Reports Q1 EPS \$0.36 vs \$0.18 Est; Revenues \$71.2M vs \$70.95M Est

Financial news for ACOR dated on 2012-03-15: Acorda Therapeutics Spiking Higher on Heavy Volume; Currently at \$26.21

Financial news for ACOR dated on 2012-03-15: UPDATE: Stifel Nicolaus Resumes Buy, \$34 Target on Acorda Therapeutics

Financial news for ACOR dated on 2012-02-17: Citigroup Downgrades Acorda Therapeutics from Buy to Neutral, Raises PT from \$27 to \$29

Financial news for ACOR dated on 2012-02-16: Acorda Therapeutics Reports Q4 EPS \$0.45 vs \$0.18 Est; Revenues \$72.6M vs \$69.16M Est

Financial news for ACOR dated on 2012-02-06: Acorda Therapeutics Announces Launch of Authorized Generic Version of ZANAFLEX CAPSULES(r)

Financial news for ACOR dated on 2012-02-06: Apotex Receives FDA Approval, Negative for Acorda Therapeutics

Financial news for ACOR dated on 2012-02-03: Acorda Therapeutics Presents Preclinical Data Showing Dalfampridine Improves Motor Function in Chronic Stroke

Financial news for ACOR dated on 2012-01-23: JP Morgan Downgrades ACOR, ALTH, AMGN, VPHM

Financial news for ACOR dated on 2011-11-15: Disclosure Insight Maintains Medium Risk Rating on Acorda Therapeutics

Financial news for ACOR dated on 2011-11-07: Piper Jaffray Neutral on Acorda Therapeutics

Financial news for ACOR dated on 2011-11-04: Rodman & Renshaw Reiterates Acorda Therapeutics Market Underperform, \$18 PT

Financial news for ACOR dated on 2011-11-04: Earnings Scheduled For November 4

Financial news for ACOR dated on 2011-10-21: Piper Jaffray Maintains Neutral Rating and \$28 PT on Acorda Therapeutics

Financial news for ACOR dated on 2011-10-13: Notable Call Options Activity in Acorda Therapeutics

Financial news for ACOR dated on 2011-09-07: JP Morgan Lowers PT On Acorda Therapeutics To \$38

Financial news for ACOR dated on 2011-09-07: Acorda Therapeutics Statement on ZANAFLEX CAPSULES Patent Litigation

Financial news for ACOR dated on 2011-08-10: A Peek Into The Market Before The Trading Starts

Financial news for ACOR dated on 2011-08-10: Acorda Therapeutics Announces Allowance of Second U.S. Patent Application for AMPYRA(r) Covering Methods of Use for Improving Walking in Multiple Sclerosis

Financial news for ACOR dated on 2011-08-02: UPDATE: Piper Jaffray Lowering Price Target On Acorda Therapeutics

Financial news for ACOR dated on 2011-08-02: Piper Jaffray Lowers PT On Acorda Therapeutics To \$28

Financial news for ACOR dated on 2011-08-01: Rodman & Renshaw Maintains Acorda Therapeutics Market Underperform, \$18 PT

Financial news for ACOR dated on 2011-08-01: Earnings Roundup

Financial news for ACOR dated on 2011-08-01: UPDATE: Acorda Therapeutics Reports Weaker-Than-Expected Q2 Earnings

Financial news for ACOR dated on 2011-08-01: Earnings Scheduled For August 1

Financial news for ACOR dated on 2011-07-11: 11 Stocks Breaking Down

Financial news for ACOR dated on 2011-07-01: A Peek Into The Market Before The Trading Starts

Financial news for ACOR dated on 2011-07-01: Acorda Therapeutics Licenses Rights to Investigational Treatment for Spinal Cord Injury and Traumatic Brain Injury

Financial news for ACOR dated on 2011-06-21: Calls Purchased on Acorda Therapeutics, Inc.

Financial news for ACOR dated on 2011-06-20: Trade Setups For 6/21

Financial news for ACOR dated on 2011-06-07: Acorda Therapeutics Jumping On Takeover Rumors

Financial news for ACOR dated on 2011-06-07: Hearing Chatter Biogen May Buy/Partner On MS Drugs

Financial news for ACOR dated on 2011-06-07: Acorda Therapeutics Spiking on Heavy Volume

Financial news for ACOR dated on 2011-06-06: New Clinical Data Analysis of AMPYRA Shows Improvement of Patient-Reported Walking Ability across a Range of Walking Impairment

Financial news for ACOR dated on 2011-06-01: Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer

Financial news for ACOR dated on 2011-06-01: Hapoalim Cutting Ocverage On Multitude Of Names

Financial news for ACOR dated on 2011-05-25: Puts Purchased on Acorda Therapeutics

Financial news for ACOR dated on 2011-05-23: Benzinga's Top Upgrades

Financial news for ACOR dated on 2011-05-23: UPDATE: Piper Jaffray Upgrading Acorda Therapeutics

Financial news for ACOR dated on 2011-05-23: Piper Jaffray Upgrades Acorda Therapeutics To Neutral, PT Raised To \$30

Financial news for ACOR dated on 2011-05-20: Benzinga's Top Pre-Market NASDAQ Gainers

Financial news for ACOR dated on 2011-05-20: EMA Panel Seeks Long-Term Efficacy Study Of Fampyra -Bloomberg

Financial news for ACOR dated on 2011-05-16: Consumer Now in Question 05-16-2011

Financial news for ACOR dated on 2011-04-15: Stifel Nicolaus Has Hold Rating On Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2011-04-15: Acorda Therapeutics Up 2.5% (ACOR)

Financial news for ACOR dated on 2011-04-15: Acorda Therapeutics Closed Significantly Higher Thursday (ACOR)

Financial news for ACOR dated on 2011-04-15: ACOR Resumes Trading (ACOR)

Financial news for ACOR dated on 2011-04-14: Acorda Therapeutics Halted, News Pending (ACOR)

Financial news for ACOR dated on 2011-04-14: Hearing Acorda Therapeutics Spike Due To FDA Related News (ACOR)

Financial news for ACOR dated on 2011-02-18: Friday's Put/Call Ratio Leaders (ACOR, IT, RDC, GGB, BID)

Financial news for ACOR dated on 2011-02-18: Options Brief: Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2011-02-18: UPDATE: Hapoalim Securities Upgrades Acorda Therapeutics To Hold; Raises PT

Financial news for ACOR dated on 2011-02-18: Piper Jaffray Downgrades Acorda Therapeutics, Lowers PT To \$16 (ACOR)

Financial news for ACOR dated on 2011-02-18: Benzinga's Top Downgrades (VCLK, ACOR, SMI, CAB)

Financial news for ACOR dated on 2011-02-18: Piper Jaffray Downgrades Acorda Therapeutics To Underweight, PT To \$16

Financial news for ACOR dated on 2011-01-31: SAC Capital Takes 5.6% Stake In Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2011-01-24: Biogen-Acorda MS Drug Faces Setback - Analyst Blog

Financial news for ACOR dated on 2011-01-24: Biogen-Acorda MS Drug Faces Setback - Analyst Blog

Financial news for ACOR dated on 2011-01-24: Piper Jaffray Lowers PT on Acorda Therapeutics Following EU Setback

Financial news for ACOR dated on 2011-01-24: Hapoalim Reiterates Sell on Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2011-01-24: Piper Jaffray Lowers PT On Acorda Therapeutics

Financial news for ACOR dated on 2011-01-21: Benzinga's Top Pre-Market NASDAQ Losers (ACOR, VVUS, SYNA, MNKD)

Financial news for ACOR dated on 2011-01-11: Ampyra Supports Acorda Yet Again - Analyst Blog

Financial news for ACOR dated on 2011-01-11: Ampyra Supports Acorda Yet Again - Analyst Blog

Financial news for ACOR dated on 2011-01-10: Accorda Therapeutics Rises 10% (ACOR)

Financial news for ACOR dated on 2011-01-10: Acorda Therapeutics Up 8.8% On Sales News (ACOR)

Financial news for ACOR dated on 2011-01-10: Benzinga's Volume Movers (ACOR, AUXL, MDSO, SONO)

Financial news for ACOR dated on 2011-01-10: Options Brief: Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2010-12-21: Biogen Strikes Deal with Neurimmune - Analyst Blog

Financial news for ACOR dated on 2010-12-21: Biogen Strikes Deal with Neurimmune - Analyst Blog

Financial news for ACOR dated on 2010-12-14: BP: Analysts' Upgrades, Downgrades

Financial news for ACOR dated on 2010-12-03: J.P. Morgan Reiterates Overweight Rating on Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2010-11-23: Positive Data on Acorda's Ampyra - Analyst Blog

Financial news for ACOR dated on 2010-11-23: Positive Data on Acorda's Ampyra - Analyst Blog

Financial news for ACOR dated on 2010-11-05: Acorda Profit Soars on Ampyra Sales - Analyst Blog

Financial news for ACOR dated on 2010-11-02: Citigroup Expects Acorda Therapeutics To Be Profitable

Financial news for ACOR dated on 2010-11-01: Hapoalim Securities Downgrades Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2010-11-01: Acorda Therapeutics Shares Fall 4.4% Despite Results (ACOR)

Financial news for ACOR dated on 2010-11-01: Acorda Therapeutics Blows By Estimates (ACOR)

Financial news for ACOR dated on 2010-10-19: Zacks #1 Rank Additions for Tuesday - Tale of the Tape

Financial news for ACOR dated on 2010-10-15: Hapoalim Securities Lowers Price Target on Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2010-10-15: Prior To 3Q Earnings, J.P. Morgan Rates The Best In Biotechnology

Financial news for ACOR dated on 2010-10-03: Biogen Cut to Neutral - Analyst Blog

Financial news for ACOR dated on 2010-08-04: Acorda Loss Narrows on Ampyra Revs - Analyst Blog

Financial news for ACOR dated on 2010-08-04: Hapoalim Securities Has \$37 Price Target On Acorda (ACOR)

Financial news for ACOR dated on 2010-07-19: Hapoalim Securities Downgrades Acorda Therapeutics to Hold (ACOR)

Financial news for ACOR dated on 2010-06-23: Protection Purchased on Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2010-06-04: Citigroup Maintains Hold Rating On Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2010-04-15: Stocks That Have Crossed 52-Week Highs (ACOR, ACTL, AMZN, ARII, AAPL)

Financial news for ACOR dated on 2010-04-15: Heavy Volume In Acorda Therapeutics (ACOR)

Financial news for ACOR dated on 2010-04-14: Stocks That Created New 52-Week Highs (AAON, ACOR, ADTN, ADVS, ATSG)

Financial news for ACOR dated on 2010-03-29: ACOR Initiated With Hold At Citigroup

Financial news for ACOR dated on 2010-03-25: Reduce Your Risk In The Initial Public Offering Market With This IPO ETF

Financial news for ACOR dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for ACOR dated on 2010-03-03: Stocks That Created New 52-Week Highs (COMS, ACGY, ACOR, ACTL, ADVS)

Financial news for ACOR dated on 2010-02-23: Acorda's Q4 Loss In-Line With Expectations; Plans To Launch MS Drug In March (ACOR)

Financial news for ACOR dated on 2010-02-17: Stocks That Created New 52-Week Highs (SMLC, APKT, ACOR, AEHR, BIIB)

Financial news for ACOR dated on 2010-02-10: Lightning Round: Jim Enthusiastic About ACOR, RMBS, VM, ERTS, CHU

Financial news for ACOR dated on 2010-02-09: Analyst Shares Top Picks In Biotechnology Sector With CNBC (AMGN, ACOR, DNDN, GILD)

Financial news for ACOR dated on 2010-02-04: Acorda (ACOR) Announces Ampyra Pricing

Financial news for ACOR dated on 2010-02-03: Benzinga's Volume Movers (APKT, AUXL, NETL, MYGN, ACOR)

Financial news for ACOR dated on 2010-02-02: Acorda Therapeutics Rallying On Heavy Volume (ACOR)

Financial news for ACOR dated on 2010-02-02: ACOR Added To JP Morgan US Analyst Focus List

Financial news for ACOR dated on 2010-01-25: Benzinga's Top Pre-Market Losers (PARD, DLTR, GENZ, SNDA, ACOR, TTHI, HCBK)

Financial news for ACOR dated on 2010-01-15: Mid Cap Biotechs May Outperform In 2010

Financial news for ACOR dated on 2009-11-02: Healthcare sector boom, predicts, Oracle hedge fund chief (THC, CEPH, ACOR)

Financial news for ACOR dated on 2009-10-27: Acorda Therapeutics (ACOR) To Announce 2009 Q3 Financial Results on November 3, 2009

Financial news for ACOR dated on 2009-10-09: Biggest Losers (SPPI, ACOR, LEAP, LXR, CLRT)